TW201018695A - 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds - Google Patents

1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds Download PDF

Info

Publication number
TW201018695A
TW201018695A TW098125512A TW98125512A TW201018695A TW 201018695 A TW201018695 A TW 201018695A TW 098125512 A TW098125512 A TW 098125512A TW 98125512 A TW98125512 A TW 98125512A TW 201018695 A TW201018695 A TW 201018695A
Authority
TW
Taiwan
Prior art keywords
group
fluoro
ethyl
dihydro
compound
Prior art date
Application number
TW098125512A
Other languages
English (en)
Chinese (zh)
Inventor
Jose L Falco
Albert Palomer
Antonio Guglietta
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41138660&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201018695(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of TW201018695A publication Critical patent/TW201018695A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW098125512A 2008-07-30 2009-07-29 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds TW201018695A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161485 2008-07-30

Publications (1)

Publication Number Publication Date
TW201018695A true TW201018695A (en) 2010-05-16

Family

ID=41138660

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098125512A TW201018695A (en) 2008-07-30 2009-07-29 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds

Country Status (16)

Country Link
US (1) US8227501B2 (cg-RX-API-DMAC7.html)
EP (1) EP2350088A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011529477A (cg-RX-API-DMAC7.html)
KR (1) KR20110041495A (cg-RX-API-DMAC7.html)
CN (1) CN102112480A (cg-RX-API-DMAC7.html)
AR (1) AR075262A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009275918A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916395A2 (cg-RX-API-DMAC7.html)
CA (1) CA2731405A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011000184A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001062A (cg-RX-API-DMAC7.html)
PE (1) PE20110208A1 (cg-RX-API-DMAC7.html)
RU (1) RU2011107443A (cg-RX-API-DMAC7.html)
TW (1) TW201018695A (cg-RX-API-DMAC7.html)
UY (1) UY32016A (cg-RX-API-DMAC7.html)
WO (1) WO2010012789A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219725B (zh) * 2010-04-16 2013-10-09 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
CN104109143B (zh) * 2013-04-22 2018-04-27 上海阳帆医药科技有限公司 一类褪黑激素(mt1-mt2)受体激动剂及其制备方法与用途
CN104326916B (zh) * 2014-10-10 2017-09-22 青岛农业大学 2‑氟‑4‑烯丙基‑6‑硝基苯酚与2‑氟‑4‑硝基‑6‑烯丙基苯酚的联合制备及用途
US10640496B2 (en) * 2016-06-17 2020-05-05 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
CN118696029A (zh) * 2021-12-24 2024-09-24 普赛洛私人有限公司 化合物
KR20240044190A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
DE3466215D1 (en) 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
AU616907B2 (en) 1987-08-17 1991-11-14 Whitby Research, Inc. Melatonin analogues
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
EP0837850B1 (en) 1995-06-27 2004-09-01 Takeda Chemical Industries, Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
US5732360A (en) 1995-09-08 1998-03-24 At & T Wireless Services And Atmel Corp Mobile telecommunication device and method used for changing wireless communication between base stations of different kinds
CN100443480C (zh) 1996-03-08 2008-12-17 武田药品工业株式会社 三环化合物及其制备和用途
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
FR2771739B1 (fr) 1997-11-28 2001-04-20 Adir Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2784375B1 (fr) 1998-10-12 2000-11-24 Adir Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2793793B1 (fr) 1999-05-19 2004-02-27 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1214944B1 (en) 1999-08-20 2009-09-23 Takeda Pharmaceutical Company Limited Composition for PERCUTANEOUS ABSORPTION with a compound having a melatonin receptor agonist activity
FR2799757B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
MXPA04012834A (es) 2002-06-21 2005-04-25 Suven Life Sciences Ltd Arilalquil indoles novedosos que tienen afinidad por el receptor de la serotonina, utiles como agentes terapeuticos, proceso para su preparacion y composiciones farmaceuticas que los contienen.
US6908931B2 (en) 2003-04-10 2005-06-21 Bristol-Myers Squibb Company Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists
WO2005062992A2 (en) 2003-12-23 2005-07-14 Abraxis Bioscience, Inc Substituted melatonin derivatives, process for their preparation, and methods of use

Also Published As

Publication number Publication date
UY32016A (es) 2010-01-29
US8227501B2 (en) 2012-07-24
CN102112480A (zh) 2011-06-29
KR20110041495A (ko) 2011-04-21
RU2011107443A (ru) 2012-09-10
AR075262A1 (es) 2011-03-23
PE20110208A1 (es) 2011-03-28
JP2011529477A (ja) 2011-12-08
CA2731405A1 (en) 2010-02-04
US20110144178A1 (en) 2011-06-16
BRPI0916395A2 (pt) 2016-02-16
EP2350088A1 (en) 2011-08-03
MX2011001062A (es) 2011-03-24
WO2010012789A1 (en) 2010-02-04
CL2011000184A1 (es) 2011-09-16
AU2009275918A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
TW201018695A (en) 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds
TW200808691A (en) New naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them
EP0789690A1 (en) N-aryl and n-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities
US12331051B2 (en) LSD derivatives, synthesis and method for treatment of diseases and disorders
US5840764A (en) Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
JP2011513460A (ja) ニコチン性アセチルコリン受容体のモジュレーターとして有用な新規のトリアリール誘導体
EP1567150B1 (fr) Derives d indole-3-carboxamide, leur preparation et leur application en therapeutique
KR20150091163A (ko) 아미노사이클로부탄 유도체들, 이들을 제조하는 방법 및 약물들로서 그들의 용도
JP5416749B2 (ja) ベンジルピペリジン化合物
WO1998033763A1 (en) Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
JPH11512108A (ja) 鎮痛薬としての光学活性フェニルピリミジン誘導体
US10519105B2 (en) KCNQ2-5 channel activator
JPH0549673B2 (cg-RX-API-DMAC7.html)
TW201416351A (zh) 吲哚羧醯胺衍生物
CN103732578B (zh) 喹啉基胰高血糖素受体调节剂
US20120088809A1 (en) 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds
JP4008059B2 (ja) 松果体ホルモン作用薬
TW200934477A (en) Indane compounds
TW200920349A (en) Compounds of 2,3-dihydro-benzofuran
JPS59184162A (ja) キノリン誘導体、その製造法及び該化合物を含有する、５―ヒドロキシトリプタミン桔抗質として使用する医薬組成物
WO1997048682A1 (en) Heterocyclylmethylamino derivatives of cyclobutene-3,4-diones as potassium channel modulators
HK1158649A (en) 1,6-dihydro-2h-3-oxa-6-aza-as-indacene compounds
JPH10204087A (ja) 縮合ピリダジン誘導体、その製造法および剤
JP2009522245A (ja) ジヒドロ−２，３−ベンゾジアゼピンの光学異性体及びその立体選択的合成
TW200920353A (en) Phenylpyrrolidine compounds